The 2024 Alzheimer's disease (AD) drug development pipeline includes 164 clinical trials assessing 127 drugs. Compared to 2023, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), and fewer new chemical entities (88 vs. 101), but a similar number of repurposed agents (39 vs. 40). The pipeline is dominated by disease-modifying therapies (DMTs), with 96 DMTs representing 76% of the drugs. DMTs are further categorized into biologics (45%) and small molecules (45%). The targets of these agents are diverse, including amyloid beta, tau, neuroinflammation, synaptic plasticity, and transmitter systems. The pipeline also includes 39 repurposed agents, which account for 31% of the current drugs and 32% of the trials. The pharmaceutical industry funds 60% of the trials, while non-industry sources fund 40%. The average time to recruit participants for Phase 1, 2, and 3 trials is 2.1, 2.5, and 3.2 years, respectively. The study highlights the need for continued investment in AD research to accelerate the development of effective therapies.The 2024 Alzheimer's disease (AD) drug development pipeline includes 164 clinical trials assessing 127 drugs. Compared to 2023, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), and fewer new chemical entities (88 vs. 101), but a similar number of repurposed agents (39 vs. 40). The pipeline is dominated by disease-modifying therapies (DMTs), with 96 DMTs representing 76% of the drugs. DMTs are further categorized into biologics (45%) and small molecules (45%). The targets of these agents are diverse, including amyloid beta, tau, neuroinflammation, synaptic plasticity, and transmitter systems. The pipeline also includes 39 repurposed agents, which account for 31% of the current drugs and 32% of the trials. The pharmaceutical industry funds 60% of the trials, while non-industry sources fund 40%. The average time to recruit participants for Phase 1, 2, and 3 trials is 2.1, 2.5, and 3.2 years, respectively. The study highlights the need for continued investment in AD research to accelerate the development of effective therapies.